Results 161 to 170 of about 1,433 (211)
Some of the next articles are maybe not open access.

Antithrombin

2013
Antithrombin (AT) is a heparin cofactor and a member of the serine protease inhibitor family (serpin). The mature AT molecule is composed of 432 amino acids and it is produced mainly in the liver. Initially, several different AT activities in plasma were reported, leading to the classification of antithrombin in a range from I to IV.
Mirta, Hepner, Vasiliki, Karlaftis
openaire   +2 more sources

Antithrombin

Thrombosis and Haemostasis, 1971
SummaryAn evaluation of the mode of action of antithrombin in the temporary inhibition of purified 3.7 S bovine thrombin was made according to traditional enzyme inhibition theory. Using enzyme clotting activity and concentration of active sites synonymously, it was observed that the binding of antithrombin to thrombin followed a second order reaction ...
Frederick A. Dombrose   +2 more
openaire   +1 more source

Antiangiogenic Antithrombin

Seminars in Thrombosis and Hemostasis, 2007
Angiogenesis is critical for several physiologic and pathophysiologic processes, and several angiogenesis inhibitors are now in clinical trials for the treatment of cancer. Antithrombin is a member of the serpin family of proteins and functions as an inhibitor of thrombin and other enzymes involved in the clotting cascade. While studying the inhibition
openaire   +2 more sources

Human Fibrinopeptides as Antithrombins

Thrombosis and Haemostasis, 1973
SummaryHuman fibrinopeptides have been isolated from purified human fibrinogen and investigations performed on their reactions with thrombin and platelets. Fibrinopeptides A and B had an inhibitory action against the proteolytic action of thrombin but fibrinopeptide A did not impair the esterolytic activity of the enzyme.
P A Castaldi
exaly   +3 more sources

Isoform composition of antithrombin in a covalent antithrombin–heparin complex

Biochemical and Biophysical Research Communications, 2003
Antithrombin (AT) circulates in two isoforms, alpha- (90-95%) and beta-AT (5-10%). AT inhibits clotting factors such as thrombin and factor Xa, a reaction catalyzed by heparin. Heparin has been used in many clinical situations but suffers from limitations such as a short intravenous half-life, bleeding risk, and the inability to inhibit thrombin bound ...
Anthony K C, Chan   +3 more
openaire   +2 more sources

Antithrombin and Heparin Antithrombin Patterns in Pre-thrombosis and Thrombosis

American Journal of Clinical Pathology, 1976
An antithrombin assay (AA) and an antithrombin assay modified by the addition of heparin (H-AA) were performed using sera from healthy subjects, patients predisposed to thrombosis, and patients with thromboembolic disease. Characteristic AA, and H-AA patterns were found in each group.
I, Innerfield   +4 more
openaire   +2 more sources

Antiplatelet and antithrombin therapy

Coronary Artery Disease, 1994
The contemporary pharmacologic treatment of acute myocardial infarction (AMI) includes reperfusion via a thrombolytic agent as well as adjunctive therapy with aspirin and heparin (1). Despite the advances made, current management is limited by the fact that infarct-related artery patency is achieved in only 60–80% of patients at 90 min and Thrombolysis
A, Fernández-Ortiz   +2 more
openaire   +2 more sources

Platelet antithrombin activity

Thrombosis Research, 1980
Abstract Platelets were studied for the presence of antithrombin (thrombin amidolytic inhibitory) activity. Platelet rich plasma contained more antithrombin activity than platelet poor plasma. This activity could be washed from a platelet pellet. Antithrombin activity increased on sonication of platelets but not following aggregation.
E E, Czapek, H C, Kwaan
openaire   +2 more sources

Antithrombin III Assays

JAMA: The Journal of the American Medical Association, 1978
To the Editor.— In a recent letter to the editor, Rodger L. Bick, MD, commented on methods of assay of antithrombin III (239:296, 1978), pointing out several drawbacks to the use of synthetic chromogenic substrates in such assays. His comments were prompted by an article in MEDICAL NEWS (238:1005, 1977) in which we reported that these peptides were ...
H L, Messmore, J, Fareed
openaire   +2 more sources

Pasteurization of antithrombin without generation of the prelatent form of antithrombin

Protein Expression and Purification, 2004
Human antithrombin (AT) is the major inhibitor of blood coagulation and has also been shown to exert anti-inflammatory and anti-angiogenic effects. Pasteurization of pharmaceutical AT products is usually performed at 60 degrees C for 10h in the presence of sodium citrate as stabilizer, sometimes in combination with sucrose.
openaire   +2 more sources

Home - About - Disclaimer - Privacy